RxDoctor Payments DataLook up a doctor →

Nathan McBride, PA

Physician Assistant · Ogden, UTNPI 1114915741

Payments from drug & device makers

$10,692in general payments, 2019–2025

Across 677 payments — averaging $15.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Johnson & Johnson$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$700
  • QOL Medical, LLC$534
  • Regeneron Healthcare Solutions, Inc.$511
  • plus $4K from 23 others

What the payments were for

  • Food & beverage$10,692100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,692 in reported general payments places this provider in the 95th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$70,921
Medicare patients
381
Services billed
2,689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab45$379,574
ZenpepLipase/Protease/Amylase60$143,508
XifaxanRifaximin38$128,902
CreonLipase/Protease/Amylase29$60,061
Mesalamine61$40,970
Dexlansoprazole DrDexlansoprazole47$20,397
LinzessLinaclotide21$11,858
Colestipol Hcl81$7,214
Ursodiol27$6,764
MovantikNaloxegol Oxalate13$5,228
CholestyramineCholestyramine (With Sugar)82$5,037
Mesalamine ErMesalamine21$4,605
Omeprazole251$4,196
Budesonide DrBudesonide24$3,397
Pantoprazole Sodium301$3,176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$309$143,50860 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$700$128,90238 claims
AbbVieCreon, Linzess$2,651$71,91950 claims
Redhill Biopharma Inc.Movantik$67$5,22813 claims
SandozLansoprazole$48$1,27833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →